Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 8.31% is 48% below its 5-year average of 16.07%, near the low end of its 5-year range (2.40%–32.79%).
As of the fiscal period ended Wednesday, December 31, 2025. 8.08% below its 12-month average of 9.04%.
Annual fiscal-year return on equity; no daily interpolation.
RETURN ON EQUITY (ROE)
8.31%
RETURN ON EQUITY (ROE) AVG TTM
9.04%
RETURN ON EQUITY (ROE) AVG 3Y
13.32%
RETURN ON EQUITY (ROE) AVG 5Y
16.07%
RETURN ON EQUITY (ROE) AVG 10Y
17.51%
RETURN ON EQUITY (ROE) AVG 15Y
15.79%
RETURN ON EQUITY (ROE) AVG 20Y
12.27%
CURRENT VS TTM AVG
-8.08%
CURRENT VS 3Y AVG
-37.60%
CURRENT VS 5Y AVG
-48.30%
CURRENT VS 10Y AVG
-52.53%
CURRENT VS 15Y AVG
-47.37%
CURRENT VS 20Y AVG
-32.26%
SECTOR MEDIAN · HEALTHCARE
10.89%
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
-23.69%
vs the sector median at left
Pfizer Inc.
Market Cap
$139.86B
Return on Equity (ROE)
8.31%
TTM Avg
9.04%
3Y Avg
13.32%
5Y Avg
16.07%
Market Cap
$137.47B
Return on Equity (ROE)
3.79%
TTM Avg
4.23%
3Y Avg
6.35%
5Y Avg
7.74%
Market Cap
$134.62B
Return on Equity (ROE)
7.61%
TTM Avg
7.38%
3Y Avg
9.51%
5Y Avg
10.24%
Market Cap
$126.79B
Return on Equity (ROE)
36.25%
TTM Avg
-8.30%
3Y Avg
7.76%
5Y Avg
4.45%
Market Cap
$126.60B
Return on Equity (ROE)
14.52%
TTM Avg
14.50%
3Y Avg
15.05%
5Y Avg
14.30%
Market Cap
$121.16B
Return on Equity (ROE)
22.41%
TTM Avg
8.96%
3Y Avg
15.60%
5Y Avg
19.47%
Market Cap
$119.23B
Return on Equity (ROE)
17.28%
TTM Avg
15.07%
3Y Avg
13.91%
5Y Avg
13.46%
Market Cap
$160.55B
Return on Equity (ROE)
39.19%
TTM Avg
19.98%
3Y Avg
21.60%
5Y Avg
19.44%
Market Cap
$106.51B
Return on Equity (ROE)
9.70%
TTM Avg
9.71%
3Y Avg
8.51%
5Y Avg
8.44%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pfizer Inc. (PFE) | $139.86B | 8.31% | 9.04% | 13.32% | 16.07% |
| CVS Health Corp. (CVS)vs › | $137.47B | 3.79% | 4.23% | 6.35% | 7.74% |
| Danaher Corporation (DHR)vs › | $134.62B | 7.61% | 7.38% | 9.51% | 10.24% |
| Bristol-Myers Squibb Company (BMY)vs › | $126.79B | 36.25% | -8.30% | 7.76% | 4.45% |
| Stryker Corporation (SYK)vs › | $126.60B | 14.52% | 14.50% | 15.05% | 14.30% |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $121.16B | 22.41% | 8.96% | 15.60% | 19.47% |
| Intuitive Surgical, Inc. (ISRG)vs › | $119.23B | 17.28% | 15.07% | 13.91% | 13.46% |
| Gilead Sciences, Inc. (GILD)vs › | $160.55B | 39.19% | 19.98% | 21.60% | 19.44% |
| Medtronic plc (MDT)vs › | $106.51B | 9.70% | 9.71% | 8.51% | 8.44% |
| GSK plc (GSK)vs › | $103.60B | 25.19% | 26.90% | 55.97% | 45.70% |
ROE
8.3%
ROA
3.6%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 8.99% |
| 2024-12-31 | 9.09% |
| 2023-12-31 | 2.40% |
| 2022-12-31 | 32.79% |
| 2021-12-31 | 28.69% |
| 2020-12-31 | 14.48% |
| 2019-12-31 | 25.77% |
| 2018-12-31 | 17.59% |
| 2017-12-31 | 29.88% |
| 2016-12-31 | 12.12% |
| 2015-12-31 | 10.76% |
| 2014-12-31 | 12.73% |
| 2013-12-31 | 15.27% |
| 2012-12-31 | 12.04% |
| 2011-12-31 | 10.59% |
| 2010-12-31 | 9.42% |
| 2009-12-31 | 9.59% |
| 2008-12-31 | 13.94% |
| 2007-12-31 | 12.63% |
| 2006-12-31 | 15.45% |
| 2005-12-31 | 11.60% |
| 2004-12-31 | 16.60% |
| 2003-12-31 | 5.98% |
| 2002-12-31 | 45.74% |
| 2001-12-31 | 42.57% |
| 2000-12-31 | 23.18% |
| 1999-12-31 | 35.77% |
| 1998-12-31 | 38.04% |
| 1997-12-31 | 27.90% |
| 1996-12-31 | 27.74% |
